SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: juneau_boy who wrote (433)4/27/2000 11:37:00 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
....another grain?

<<Contract manufacturing expense was higher due to costs associated with initiating commercial production of both a vaccine intermediate for Merck and BDNF for clinical use by Sumitomo Pharmaceuticals Co., Ltd. Research and development expense rose because of higher staffing and increased activity in Regeneron's preclinical and clinical research programs.>>

Another several grains!